© Copyright RiverVest® All Rights Reserved.
Biopharma – Small Molecule – Rare/Orphan Disease
Year Invested: 2017
OxaluRx is a preclinical biopharmaceutical company developing a small molecule glycolate oxidase inhibitor to treat conditions resulting from high oxalate levels, including recurrent kidney stone disease.
© Copyright RiverVest® All Rights Reserved.